Ionis Pharmaceuticals, Inc. Equity Method Investment, Summarized Financial Information, Current Liabilities (Deprecated 2020-01-31)
Ionis Pharmaceuticals, Inc. (IONS) had Equity Method Investment, Summarized Financial Information, Current Liabilities (Deprecated 2020-01-31) of $12.85 million as of 2011-12-31, per its 10-K filed 2012-02-29.
Discontinued › Notes
us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities · last filed 2012-02-29
- 2011-12-31: Equity Method Investment, Summarized Financial Information, Current Liabilities (Deprecated 2020-01-31) $12.85M.
- 2010-12-31: Equity Method Investment, Summarized Financial Information, Current Liabilities (Deprecated 2020-01-31) $14.73M.
| Period end | Equity Method Investment, Summarized Financial Information, Current Liabilities (Deprecated 2020-01-31) |
|---|---|
| 2011-12-31 | $12.85M 10-K · filed 2012-02-29 |
| 2010-12-31 | $14.73M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |